基于治疗前MR影像特征预测孤立性小肝癌切除后结局:按甲胎蛋白表达分组的亚组分析
回顾性纳入201例经病理诊断并接受MRI的孤立性小肝癌患者,分为甲胎蛋白阴性组(n=85)和甲胎蛋白阳性组(n=116),用Cox分析建立预测无复发生存率的模型。甲胎蛋白阴性组预测因子为马赛克结构、门静脉期肿瘤与右侧竖脊肌信号强度比和球形度,甲胎蛋白阳性组为肝硬化、肿瘤生长亚型和去球形度;两模型C指数分别为0.700和0.717,均可将各组分为生存结局显著不同的两个风险组(p < 0.001)。
要点
- 甲胎蛋白阴性小肝癌的RFS预测因子为马赛克结构、门静脉期信号强度比和球形度。
- 甲胎蛋白阳性小肝癌的RFS预测因子为肝硬化、肿瘤生长亚型和去球形度。
- 两模型C指数分别为0.700和0.717,风险分层后组间生存差异p < 0.001。
核心结论
- 两个预后模型可能帮助医生对甲胎蛋白阴性或阳性孤立性小肝癌患者进行风险分层和复发监测。
研究设计与样本
- 回顾性纳入201例经病理诊断的孤立性小肝癌患者,均行MRI,分为甲胎蛋白阴性组(n=85)和甲胎蛋白阳性组(n=116),用单因素和多因素Cox分析确定与RFS相关的临床病理因素、影像特征和几何参数,建立两个预后模型并用C指数评价及内部验证。
关键影像表现/征象
- 甲胎蛋白阴性组RFS预测因子为马赛克结构、门静脉期肿瘤与右侧竖脊肌信号强度比和球形度。
- 甲胎蛋白阳性组RFS预测因子为肝硬化、肿瘤生长亚型和去球形度。
诊断标准与关键数值
- 甲胎蛋白阴性组模型预测RFS的C指数为0.700。
- 甲胎蛋白阳性组模型预测RFS的C指数为0.717。
- 两模型计算的风险概率将两个亚组分别分为生存结局显著不同的两个风险组(p < 0.001)。
临床应用与阅片要点
- 作者认为两模型可能帮助医生对不同甲胎蛋白表达的孤立性小肝癌患者进行风险分层和复发监测。
- 作者认为模型可指导临床医生对不同甲胎蛋白表达的小肝癌患者制定适当治疗决策和实施术后监测方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop models including MRI features for predicting recurrence-free survival (RFS) in patients with solitary small hepatocellular carcinoma (SHCC) following curative resection according to alpha-fetoprotein (AFP) expression and for achieving risk stratification.
MATERIALS AND METHODS: A total of 201 solitary SHCC patients diagnosed pathologically who underwent MRI were enrolled retrospectively and divided into AFP-negative (n = 85) and AFP-positive (n = 116) SHCC groups. Clinicopathological factors, imaging features, and geometric parameters associated with RFS were determined by univariate and multivariate Cox analyses. Two prognostic models predicting postresection RFS were developed by multivariate Cox proportional hazard model, and their discriminatory ability was evaluated by the concordance index (C-index) and conducted internal validation. Kaplan‒Meier analysis with RFS as the endpoint was used to assess model performance.
RESULTS: The predictors of RFS in AFP-negative SHCC included mosaic architecture, portal-venous phase tumor-to-right erector spinae muscle signal intensity ratio, and sphericity, whereas those in AFP-positive SHCC were liver cirrhosis, tumor growth subtype, and asphericity. The C-indexes of the models in predicting RFS in AFP-negative and AFP-positive SHCC were 0.700 and 0.717, respectively. The risk probability calculated with the models stratified the two patient subgroups into two risk groups with significantly different survival outcomes (p < 0.001).
CONCLUSION: Our two prognostic models may assist physicians in stratifying risk and monitoring relapses in patients with AFP-negative or AFP-positive solitary SHCCs.
KEY POINTS: Question This study explored the predictors of the postresection outcomes of patients with small hepatocellular carcinoma according to the level of alpha-fetoprotein expression. Findings Pretreatment MRI and geometric features can serve as prognostic markers for predicting postoperative recurrence-free survival of small hepatocellular carcinoma with different alpha-fetoprotein expression. Clinical relevance Our models guide clinicians in administering appropriate therapeutic decisions and implementing proper postoperative monitoring regimens in different alpha-fetoprotein expression small hepatocellular carcinoma patients.
引用
- Song W, Xu Y, Zhou J, et al. Predicting postresection outcomes in solitary small hepatocellular carcinoma via pretreatment MR imaging features: subgroup analysis according to alpha-fetoprotein expression. Eur Radiol. 2025. PMID: 40214735. doi:10.1007/s00330-025-11558-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。